SCHEMBL28647145

SCHEMBL28647145

NC(=NN=Cc1ccncc1Cl)NCC(=O)O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 4/20 0.37
GRIN3B O60391 4/20 0.37
GRIN1 Q05586 4/20 0.37
GRIN2A Q12879 4/20 0.37
GRIN2B Q13224 4/20 0.37
GRIN2C Q14957 4/20 0.37
GRIN3A Q8TCU5 4/20 0.37
NPSR1 Q6W5P4 3/20 0.35
MAPT P10636 2/20 0.35
EGLN1 Q9GZT9 3/20 0.34
HIF1A Q16665 2/20 0.33
GRK2 P25098 1/20 0.33
POLB P06746 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
LMNA P02545 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
TSHR P16473 1/20 0.33
BLM P54132 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28657657 0.77 GRIN2D (0.60) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL22431375 0.69 HTT (0.36) NPSR1MAPTGRK2POLBLMNA
Acetic Acid SCHEMBL17395931 0.68 KDM4E (0.39) MAPTGRK2POLBLMNACYP1A2
Acetic Acid SCHEMBL17395930 0.68 KDM4E (0.39) MAPTGRK2POLBLMNACYP1A2
SCHEMBL4637840 0.66 GAA (0.42) TSHRL3MBTL1KDM4E
SCHEMBL4637844 0.66 GAA (0.42) TSHRL3MBTL1KDM4E
SCHEMBL15157563 0.66 CCNC (0.41) NPSR1MAPTCA1CA2LMNA
SCHEMBL15875058 0.65 KMT2A (0.39) NPSR1MAPTPOLBLMNAL3MBTL1
SCHEMBL15875061 0.65 KMT2A (0.39) NPSR1MAPTPOLBLMNAL3MBTL1
SCHEMBL18474178 0.64 MEN1 (0.39) MAPTGRK2LMNAL3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107074752-B Therapeutic use of benzylidene guanidine derivatives for the treatment of protein conformation disorders 英费列特斯生命科学公司 2021-10-26 CN disclosed